Date:____May. 13th, 2021____

Consulting fees

X__None

Your Name:Hengzhe Zhang				
			n and migration, and induces apoptosis in bladder care	<u>cinoma</u>
Ma	anuscript number (if known)	: TAU-21-	409	
rel pa to rel	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmen of the manuscript of the doubt about whether to list a so. ps/activities/interests as they relate to the current	
	anuscript only.	to the author's relationship	psy activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hyperte edication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reporte	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertens the manuscript. d in this manuscript without time limit. For all other in	ive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None		
3	Royalties or licenses	XNone		

	1	I	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
,	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
_0	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
42		V None	
13	Other financial or non-	XNone	
	financial interests		
ΡΙΔ	ease summarize the above o	onflict of interest in the fol	lowing hox:
- ' '			
	None.		

Date:____May. 13th, 2021___

Consulting fees

X__None

Your Name:Xiang Bao Manuscript Title: <u>Devazepide suppresses cell proliferation and migration</u> , and induces apoptosis in bladder carcinoma				
	anuscript number (if known)			<u>.iiioiiia</u>
rel pa to rel	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" me e affected by the content on necessarily indicate a bias. it is preferable that you do	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so. Ips/activities/interests as they relate to the current	
ma	nuscript only.			
to	•	ension, you should declare	defined broadly. For example, if your manuscript pertal all relationships with manufacturers of antihypertensions the manuscript.	
	item #1 below, report all su e time frame for disclosure i	•	d in this manuscript without time limit. For all other it	ems,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	l planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None		
3	Royalties or licenses	XNone		

5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
	·		
7	Support for attending	X None	
	meetings and/or travel		
	, , , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	^_NOTIE	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
10	financial interests		
	indicial interests		
DI	ease summarize the above o	onflict of interest in the fol	lowing hov:
rit	case summanize the above to	ommet of interest in the for	IIOWIIIE DOV.
	None		
	None.		

Yo Ma	te:May. 13 th , 2021 ur Name:Jian Zhang nnuscript Title: <u>Devazepide s</u> nnuscript number (if known)	suppresses cell proliferati	on and migration, and induces apoptosis in bladder carcinom I-409	<u>а</u>
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment is. If you are in doubt about whether to list a lo so.	
	e following questions apply inuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hyperto dication, even if that medic	ension, you should declar cation is not mentioned in pport for the work report	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items,	
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		needed) Time frame: Since the initial	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: pas	st 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		

4

Consulting fees

_X__None

5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
	·		
7	Support for attending	X None	
	meetings and/or travel		
	, , , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	^_NOTIE	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
10	financial interests		
	indicial interests		
DI	ease summarize the above o	onflict of interest in the fol	lowing hov:
rit	case summanize the above to	ommet of interest in the for	IIOWIIIE DOV.
	None		
	None.		

Date:____May. 13th, 2021____

Royalties or licenses

Consulting fees

4

X__None

X__None

Yo	ur Name:Qiang Hu			
Ma	anuscript Title: <u>Devazepide s</u>		on and migration, and induces apoptosis in bladder carci	<u>noma</u>
Ma	anuscript number (if known)): TAU-21	409	
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to me	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,			
	e time frame for disclosure i		,	,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	al planning of the work	
L	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: pas	t 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		

	1	I	
5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
,	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
_0	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
42		V None	
13	Other financial or non-	XNone	
	financial interests		
ΡΙΔ	ease summarize the above o	onflict of interest in the fol	lowing hox:
- ' '			
	None.		

	te:May. 13 th , 2021	_				
	Your Name:Bingbing Wei					
			n and migration, and induces apoptosis in bladder card	<u>inoma</u>		
M	anuscript number (if known)): TAU-21	-409			
		-	I relationships/activities/interests listed below that are	!		
	-		ans any relation with for-profit or not-for-profit third			
-		-	of the manuscript. Disclosure represents a commitment	ţ		
	•		If you are in doubt about whether to list a			
rel	ationship/activity/interest,	it is preferable that you do) so.			
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>			
TL		:.::::	defined by addy. For average if your many and in a contract to the			
			defined broadly. For example, if your manuscript pertagral relationships with manufacturers of antihypertensi			
		• •	•	ve		
me	edication, even if that medic	ation is not mentioned in	the manuscript.			
	item #1 below, report all su e time frame for disclosure i	•	d in this manuscript without time limit. For all other it	ems,		
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as	·			
		needed)				
		Time frame: Since the initia	l planning of the work			
1	All support for the present	X None				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time frame: past	36 months			
2	Grants or contracts from	X None				
_	any entity (if not indicated					
	in item #1 above).					
3	Royalties or licenses	X None				
	,					

Consulting fees

_X__None

5	lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
	·		
7	Support for attending	X None	
	meetings and/or travel		
	, , , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	^_NOTIE	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
10	financial interests		
	indicial interests		
DI	ease summarize the above o	onflict of interest in the fol	lowing hov:
rit	case summanize the above to	omination interest in the loi	IIOWIIIE DOV
	None		
	None.		